stockrowBioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
Follow BNTX
Alert me
BioNTech SE Sponsored ADR (BNTX) EBITDA
BioNTech SE Sponsored ADR's EBITDA for fiscal 2025 was −$1.2B, compared with −$1.1B in fiscal 2024. Over the twelve months to 30 September 2026 it was −$1.1B. Over the past ten years it has ranged from −$1.2B (fiscal 2025) to $18.2B (fiscal 2021) — the current reading is the lowest in ten years. EBITDA has fallen for 4 consecutive fiscal years. BioNTech SE Sponsored ADR ranks 592nd of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$1.2B | — |
| FY2024 | −$1.1B | — |
| FY2023 | $945.7M | (92.97%) |
| FY2022 | $13.5B | (25.98%) |
| FY2021 | $18.2B | — |
| FY2020 | −$49.9M | — |
| FY2019 | −$165.3M | — |
| FY2018 | −$37.6M | — |
| FY2017 | −$60.0M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $521.8M | — |
| Jun 2026 | −$793.9M | — |
| Mar 2026 | −$651.0M | — |
| Dec 2025 | −$224.9M | — |
| 24 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| GMAB Genmab A/S Sponsored ADR compare | $1.2B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $1.0B |
| EXEL Exelixis, Inc. compare | $1.0B |
| INCY Incyte Corporation compare | $724.9M |
| ASND Ascendis Pharma A/S compare | $321.3M |
| BBIO BridgeBio Pharma, Inc. compare | −$352.4M |
| INSM Insmed, Inc. compare | −$531.4M |
| ROIV Roivant Sciences Ltd. compare | −$593.3M |
| BNTX BioNTech SE Sponsored ADR | −$1.1B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on BNTX
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement